Good news for Apotex: Plavix gets another approval
Had BMS and S-A known they were going to lose patent protection through their own legal blunders, they probably wouldn't have conducted the COMMIT and CLARITY studies which led to this additional approval. (Trials cost money, you know.)
Two studies support the effectiveness of Plavix in treating STEMI heart attack patients. A large trial, the Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) study, demonstrated that Plavix, when combined with other standard treatments including thrombolysis, a procedure to dissolve clots, reduced mortality and also reduced the combined number of recurrent heart attacks, strokes and deaths. COMMIT was a randomized, double-blind, placebo-controlled trial of 46,000 patients conducted in China.
The findings in COMMIT in China are supported by the results of the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) study. CLARITY was a clinical trial of 3,500 patients undergoing thrombolysis for STEMI heart attacks. CLARITY showed that the coronary artery blood flow was better with clopidogrel treatment compared to placebo.
So who benefits from this? Patients and Apotex. Hilarity ensues.
[tags]Medicine, pharmacy, plavix, clopidogrel, COMMIT, BMS, Sanofi-Aventis, clopidogrel, Apotex[/tags]
No Comments »
No comments yet.
RSS feed for comments on this post.
| TrackBack URI
You can also bookmark
this on del.icio.us or check the cosmos